ProStrakan/Endo's testosterone gel faces US setback
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter to ProStrakan/Endo Pharmaceutical over Fortesta (testosterone, 2% gel), which was filed for the treatment of men with hypogonadism.